ALBERT MIGUELA BENAVIDES

Albert Miguела Benavides is a Pre-doctoral Researcher (R1) affiliated with the Neurodegeneration and Neuroinflammation research group. He contributes to projects like PROCOGBIO (PI23/00517), funded by Instituto de Salud Carlos III, which investigates biomarkers for predicting cognitive decline in multiple sclerosis (MS). His work focuses on translational research at the intersection of clinical neurology and biomarker discovery.

Research interests include neuroinflammation mechanisms, neurodegenerative processes in MS, and the application of circulating biomarkers (e.g., miRNAs, cytokines) to predict disease progression and treatment outcomes. He collaborates with multidisciplinary teams analyzing both serum/cerebrospinal fluid markers and neuroimaging data.

Publications from 2024 highlight investigations into calcitriol therapy for Friedreich ataxia, ozanimod discontinuation effects, and IL-8/IL-6 as cognitive biomarkers. His work emphasizes developing clinical tools for early intervention and personalized medicine in neurodegenerative diseases.

Currently engaged in the 3-year PROCOGBIO project (2024-2026) led by Dr. LLuís Ramió Torrentà, he contributes to longitudinal studies tracking cognitive trajectories in MS patients. No awards are explicitly listed, but his active participation in high-impact studies indicates strong research engagement.